These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. ACU193, a Monoclonal Antibody that Selectively Binds Soluble Aß Oligomers: Development Rationale, Phase 1 Trial Design, and Clinical Development Plan. Siemers E; Hitchcock J; Sundell K; Dean R; Jerecic J; Cline E; Iverson K; Moore J; Edgar C; Manber R; Fuin N; Poppe T; Barton R J Prev Alzheimers Dis; 2023; 10(1):19-24. PubMed ID: 36641606 [TBL] [Abstract][Full Text] [Related]
6. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. Salloway S; Sperling R; Fox NC; Blennow K; Klunk W; Raskind M; Sabbagh M; Honig LS; Porsteinsson AP; Ferris S; Reichert M; Ketter N; Nejadnik B; Guenzler V; Miloslavsky M; Wang D; Lu Y; Lull J; Tudor IC; Liu E; Grundman M; Yuen E; Black R; Brashear HR; N Engl J Med; 2014 Jan; 370(4):322-33. PubMed ID: 24450891 [TBL] [Abstract][Full Text] [Related]
7. Safety and tolerability of BAN2401--a clinical study in Alzheimer's disease with a protofibril selective Aβ antibody. Logovinsky V; Satlin A; Lai R; Swanson C; Kaplow J; Osswald G; Basun H; Lannfelt L Alzheimers Res Ther; 2016 Apr; 8(1):14. PubMed ID: 27048170 [TBL] [Abstract][Full Text] [Related]
8. A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Safety, Pharmacokinetics, and Biomarker Results of Subcutaneous Bapineuzumab in Patients with mild to moderate Alzheimer's disease. Brody M; Liu E; Di J; Lu M; Margolin RA; Werth JL; Booth K; Shadman A; Brashear HR; Novak G J Alzheimers Dis; 2016 Oct; 54(4):1509-1519. PubMed ID: 27589523 [TBL] [Abstract][Full Text] [Related]
9. Safety, Tolerability, and Pharmacokinetics of Crenezumab in Patients with Mild-to-Moderate Alzheimer's Disease Treated with Escalating Doses for up to 133 Weeks. Guthrie H; Honig LS; Lin H; Sink KM; Blondeau K; Quartino A; Dolton M; Carrasco-Triguero M; Lian Q; Bittner T; Clayton D; Smith J; Ostrowitzki S J Alzheimers Dis; 2020; 76(3):967-979. PubMed ID: 32568196 [TBL] [Abstract][Full Text] [Related]
10. At-Home Administration of Gantenerumab by Care Partners to People with Early Alzheimer's Disease: Feasibility, Safety and Pharmacodynamic Impact. Boess FG; Scelsi MA; Grimmer T; Perry RJ; Tonietto M; Klein G; Hofmann C; Salami M; Wojtowicz J; Lansdall CJ; Lane C; Kerchner GA; Smith J; Doody RS J Prev Alzheimers Dis; 2024; 11(3):537-548. PubMed ID: 38706270 [TBL] [Abstract][Full Text] [Related]
11. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. Doody RS; Thomas RG; Farlow M; Iwatsubo T; Vellas B; Joffe S; Kieburtz K; Raman R; Sun X; Aisen PS; Siemers E; Liu-Seifert H; Mohs R; ; N Engl J Med; 2014 Jan; 370(4):311-21. PubMed ID: 24450890 [TBL] [Abstract][Full Text] [Related]
12. A Randomized, Double-Blind, Phase 2 Study of the Effects of the Vaccine Vanutide Cridificar with QS-21 Adjuvant on Immunogenicity, Safety and Amyloid Imaging in Patients with Mild to Moderate Alzheimer's Disease. Ketter N; Liu E; Di J; Honig LS; Lu M; Novak G; Werth J; LePrince Leterme G; Shadman A; Brashear HR J Prev Alzheimers Dis; 2016; 3(4):192-201. PubMed ID: 29199321 [TBL] [Abstract][Full Text] [Related]
13. Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease. Budd Haeberlein S; Aisen PS; Barkhof F; Chalkias S; Chen T; Cohen S; Dent G; Hansson O; Harrison K; von Hehn C; Iwatsubo T; Mallinckrodt C; Mummery CJ; Muralidharan KK; Nestorov I; Nisenbaum L; Rajagovindan R; Skordos L; Tian Y; van Dyck CH; Vellas B; Wu S; Zhu Y; Sandrock A J Prev Alzheimers Dis; 2022; 9(2):197-210. PubMed ID: 35542991 [TBL] [Abstract][Full Text] [Related]
14. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody. Swanson CJ; Zhang Y; Dhadda S; Wang J; Kaplow J; Lai RYK; Lannfelt L; Bradley H; Rabe M; Koyama A; Reyderman L; Berry DA; Berry S; Gordon R; Kramer LD; Cummings JL Alzheimers Res Ther; 2021 Apr; 13(1):80. PubMed ID: 33865446 [TBL] [Abstract][Full Text] [Related]
15. First-In-Human safety and long-term exposure data for AAB-003 (PF-05236812) and biomarkers after intravenous infusions of escalating doses in patients with mild to moderate Alzheimer's disease. Delnomdedieu M; Duvvuri S; Li DJ; Atassi N; Lu M; Brashear HR; Liu E; Ness S; Kupiec JW Alzheimers Res Ther; 2016 Mar; 8(1):12. PubMed ID: 26925577 [TBL] [Abstract][Full Text] [Related]
16. Bapineuzumab for mild to moderate Alzheimer's disease in two global, randomized, phase 3 trials. Vandenberghe R; Rinne JO; Boada M; Katayama S; Scheltens P; Vellas B; Tuchman M; Gass A; Fiebach JB; Hill D; Lobello K; Li D; McRae T; Lucas P; Evans I; Booth K; Luscan G; Wyman BT; Hua L; Yang L; Brashear HR; Black RS; Alzheimers Res Ther; 2016 May; 8(1):18. PubMed ID: 27176461 [TBL] [Abstract][Full Text] [Related]
17. Lecanemab in Early Alzheimer's Disease. van Dyck CH; Swanson CJ; Aisen P; Bateman RJ; Chen C; Gee M; Kanekiyo M; Li D; Reyderman L; Cohen S; Froelich L; Katayama S; Sabbagh M; Vellas B; Watson D; Dhadda S; Irizarry M; Kramer LD; Iwatsubo T N Engl J Med; 2023 Jan; 388(1):9-21. PubMed ID: 36449413 [TBL] [Abstract][Full Text] [Related]